Navigation Links
Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
Date:3/10/2008

- Formulation Has Potential to Address Large Acute Pain Prescription Drug

Market -

LAVAL, QC, March 10 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has begun enrolling patients in its Phase III clinical trial for its twice-daily, tramadol-acetaminophen combination product (study 06CCL3-001).

"Tramadol-acetaminophen combination products have become widely prescribed based on their ability to provide the analgesic potency of tramadol and the rapid efficacy of acetaminophen, as well as their use in treating a broad spectrum of pain types," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Our formulation has the potential to be the first twice-daily tramadol-acetaminophen product, as well as to compete in the broader acute pain prescription drug market globally. Accordingly, it would be an excellent complement to our once-daily tramadol product for the treatment of persistent pain."

Currently marketed tramadol-acetaminophen combination products must be administered four- to six-times per day. Labopharm believes that by metering the release of both tramadol and acetaminophen from a single tablet using its Contramid(R) controlled-release technology, its formulation has the potential to offer enhanced patient compliance through twice-daily administration, as well as a potentially improved side effect profile. More importantly, based on its potential potency, efficacy, safety and convenience, the Company's novel formulation of tramadol-acetaminophen could be well positioned as an alternative to other prescription products for the treatment of mild to moderate acute pain, including mild-opioids, tramadol, COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs) and combination forms of these products.

Study 06CCL3-001 is a multi-centre, randomized, double-blind, parallel-arm study that will compare the efficacy and safety of Labopharm's twice-daily tramadol-acetaminophen combination product to placebo in the treatment of acute low back pain. The study, which is being conducted at more than 20 centers in the U.S. and Canada, has a treatment period of approximately one week and is expected to include more than 250 patients.

About the Acute Pain Prescription Market

The number of prescriptions written for acute pain products (mild-opioids, tramadol, COX-2 inhibitors, non-steroidal anti-inflammatory drugs and combinations forms of these products) in the U.S. alone in 2007 grew to 290 million and accounted for sales of US$9.0 billion.

About Tramadol-Acetaminophen Combination Products

Tramadol-acetaminophen combination products offer the analgesic strength of tramadol and the rapid analgesia of acetaminophen in a single tablet. Tramadol-acetaminophen combination products were first launched in 2001 in the United States and in 2003 in other major markets and are indicated for the short-term (five days or less) management of acute pain in the US and the symptomatic treatment of moderate to severe pain in the rest of the world. Tramadol-acetaminophen combination products are currently available only in formulations that must be administered four- to six-times per day.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the outcomes of clinical trials, to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University of Maryland have ... same kind of electrical energy that the body uses. , In ordinary batteries ... flow of electrons out of the battery is generated by moving positive ions from ...
(Date:7/24/2017)... ... 2017 , ... SignatureCare Emergency Center is looking to award their ... to a deserving student. Get your applications in now as the deadline is ... Castillo who is a nursing student at Prairie View A&M University with a 3.45 ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... opportunity that helps high school girls succeed in STEM programs as well as ... Goodwill will host over 20 high school girls at their corporate headquarters on ...
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum in ... take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland Rockside ... a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is sponsored ...
(Date:7/24/2017)... ... July 24, 2017 , ... The ... to promote awareness for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After ... leading causes of long term skin conditions, including cancer. In the short ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, ... program to patients who suffer from painful intercourse and other painful pelvic ... vaginal atrophy due to menopause. ... VuVatech LLC ... created by Sarasota, Florida -based start-up company, VuVatech LLC, ...
Breaking Medicine Technology: